| A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab | |
| Xu, Binghe; Ma, Fei; Ouyang, Quchang; Li, Wei; Jiang, Zefei; Tong, Zhongsheng; Liu, Yunjiang; Li, Huiping; Yu, Shiying; Feng, Jifeng | |
| 2018 | |
| 会议名称 | CANCER RESEARCH |
| 会议日期 | 2018-02-01 |
| 收录类别 | CPCI-S |
| URL标识 | 查看原文 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6360432 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Xu, Binghe,Ma, Fei,Ouyang, Quchang,et al. A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[C]. 见:CANCER RESEARCH. 2018-02-01. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论